On August 3, Alnylam Pharmaceuticals rose 5.47% in regular trading, trading at approximately $218.82/share, with turnover of $174 million. The rebound follows a 28%-plus single-day plunge on July 30 triggered by Q2 revenue missing expectations and a full-year guidance cut.

Multiple institutions maintained positive ratings after the selloff, calling the decline overdone. RBC Capital Markets kept its Outperform rating while lowering its price target to $350 from $445, noting Amvuttra growth and pipeline progress still support upside. Stifel maintained a Buy rating with a $318 target. The company's Q2 adjusted EPS of $1.84 beat consensus of $1.55 by 18.71%, representing a 475% year-over-year increase. Management reaffirmed its target of delivering over 25% total revenue CAGR through 2030, though RBC noted the language appeared more measured. The full-year net product revenue guidance was lowered to $4.70-$5.10 billion from $4.90-$5.30 billion as second-line Amvuttra demand normalized. The collective institutional support eased market panic and drove a technical rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)